Compare Citius Pharmaceuticals Inc (CTXR) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Open Text Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Open Text Corporation trades at $23.63 (market cap $5.61B). The key difference: Open Text Corporation is far larger — about 411.9× Citius Pharmaceuticals Inc's market cap, and Open Text Corporation pays a 4.82% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Open Text Corporation for 23 Days on average.
| CTXR | OTEX | |
|---|---|---|
Market Cap | $13.62M | $5.61B |
Volume | 132,438 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $1.82 | $39.69 |
52-Week Low | $0.48 | $20.01 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $3.79M | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
OTEX trades at $23.52, up 1.64% today, with a bearish technical signal despite recent earnings beats. The stock is attractively valued with a P/E of 9.01 and P/S of 1.1, supported by strong profitability margins. Recent news highlights debt restructuring and a strategic AI partnership with Cohere, while cash flow trends show operational strength but negative net cash flow.
The outlook is mixed: valuation discounts and cloud growth present opportunity, but high debt and bearish technicals pose risks. Analyst consensus is a Buy with a $28.30 target, implying potential upside, though execution on AI initiatives and debt management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
